*ST赛隆：拟通过公开挂牌方式转让所持有的全资子公司赛隆生物100%股权

Group 1 - The company *ST Sailong plans to increase its investment in its wholly-owned subsidiary Hunan Sailong Biopharmaceutical Co., Ltd. by converting its debt of 49,542,778.28 yuan into equity, raising the subsidiary's registered capital from 55 million yuan to 104.5422778 million yuan, while maintaining a 100% ownership stake [1] - The debt being converted into equity is free from any pledges, disputes, or judicial measures, indicating a clean financial position for the debt [1] - The company intends to optimize resource allocation and enhance operational efficiency by publicly transferring 100% equity of Sailong Biopharmaceutical, with the transfer price based on an evaluation report [1] Group 2 - As of the report, *ST Sailong has a market capitalization of 2.3 billion yuan [2] - The revenue composition for *ST Sailong in the first half of 2025 shows that the pharmaceutical manufacturing sector accounts for 59.82%, the electronics sector for 39.78%, and other businesses for 0.4% [1]